Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sanofi ( (SNY) ) has shared an announcement.
On October 22, 2025, Sanofi announced that its investigational drug, efdoralprin alfa, met all primary and key secondary endpoints in a phase 2 study for alpha-1 antitrypsin deficiency (AATD) emphysema. The drug showed superiority over standard plasma-derived therapy, offering less frequent dosing and maintaining higher functional AAT levels, which could significantly improve treatment convenience for patients. These results highlight the potential of efdoralprin alfa as a restorative recombinant therapy, reinforcing Sanofi’s commitment to addressing unmet medical needs in rare and respiratory conditions. The study’s positive outcomes may enhance Sanofi’s industry positioning and offer new hope to stakeholders in the AATD community.
The most recent analyst rating on (SNY) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
Spark’s Take on SNY Stock
According to Spark, TipRanks’ AI Analyst, SNY is a Outperform.
Sanofi’s overall stock score is driven by strong earnings call performance and attractive valuation. Financial stability and solid profitability support the score, despite some challenges in cash flow and revenue growth. Technical analysis indicates a stable market position, contributing to a positive outlook.
To see Spark’s full report on SNY stock, click here.
More about Sanofi
Sanofi is a research and development-driven, AI-powered biopharmaceutical company dedicated to improving lives and achieving growth. The company focuses on creating innovative medicines and vaccines, leveraging its deep understanding of the immune system to address urgent healthcare, environmental, and societal challenges. Sanofi is listed on EURONEXT and NASDAQ.
Average Trading Volume: 3,133,039
Technical Sentiment Signal: Strong Buy
Current Market Cap: $124.2B
Learn more about SNY stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “You’re Going to Burn This Billion Dollars.” Microsoft Stock (NASDAQ:MSFT) Slumps on Original Assessment of OpenAI
- “7.5 Years Has Felt like a Long Time to Wait.” Sam Altman Wants His Roadster Deposit Back, Tesla Stock (NASDAQ:TSLA) Jumps Regardless
- 3 ‘Strong Buy’ Crypto Stocks with Over 100% Upside Potential, 10/31/25